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In neonatal rat stratum corneum (SC), pH declines from pH 6.8 at birth to adult levels (pH 5.0–5.5) over 5–6 d. Liver X
receptor (LXR) activators stimulate keratinocyte differentiation, improve permeability barrier homeostasis, and
accelerate the in utero development of the SC. In this manuscript we determined the effect of LXR activators on SC
acidiﬁcation in the neonatal period and whether these activators correct the functional abnormalities in perme-
ability barrier homeostasis and SC integrity/cohesion. Formation of the acid SC-buffer system was accelerated by
topically applying the LXR activator, 22(R)-hydroxycholesterol, and non-oxysterol activators of LXR, TO-901317,
and GW-3965. A sterol which does not activate LXR had no effect. LXR activation increased secretory phospholi-
pase A2 (sPLA2) activity and conversely, inhibition of sPLA2 activity prevented the LXR induced increase in SC
acidiﬁcation, suggesting that increasing sPLA2 accounts in part, for the LXR stimulation of acidiﬁcation. LXR
activation resulted in an improvement in permeability barrier homeostasis, associated with an increased matu-
ration of lamellar membranes attributable to an increased b-glucocerebrosidase activity. SC integrity cohesion also
normalized in LXR-activator-treated animals and was associated with an increase in corneodesmosomes and in
desmoglein 1 expression. These results demonstrate that LXR activators stimulate the formation of an acidic SC
and improve both permeability barrier homeostasis and SC integrity/cohesion.
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That the surface of the skin is acidic (acidic stratum corn-
eum (SC)-buffer system) has been recognized for decades
(Heuss, 1892; Schade, 1928; Marchionini and Hausknecht,
1938; Blank, 1939; Bernstein and Hermann, 1942; Draize,
1942; Arbenz, 1952; Behrendt and Green, 1958; Beare et al,
1960; Jolly, 1960; Baden and Pathak, 1967; Tippelt, 1969;
Braun-Falco and Korting, 1986; Zlotogorski, 1987; Korting
et al, 1990; Seidenari and Giusti, 1995; Berardesca et al,
1998; Yosipovitch et al, 1998; Eberlein-Konig et al, 2000;
Fluhr et al, 2000), but the mechanisms that account for its
acidification are still not completely understood. It is pos-
tulated that exogenous pathways (originating outside the
epidermis), such as microbial metabolites (Di Marzio et al,
1999), free fatty acids of pilosebaceous origin (Puhvel et al,
1975; Bibel et al, 1989), and eccrine gland-derived products
(Ament et al, 1997), such as lactic acid (Thueson et al,
1998), contribute to SC acidification. Additionally, recent
studies have shown that endogenous pathways are also
important for SC acidification (Fluhr et al, 2001a, 2004a;
Behne et al, 2002). Generation of cis-urocanic acid from
histidine (Schwarz et al, 1986; Krien and Kermici, 2000), free
fatty acid generation from phospholipid hydrolysis cataly-
zed by secretory phospholipase A2 (sPLA2) (Mao-Qiang
et al, 1996; Fluhr et al, 2001a, 2004a), and a sodium/proton
pump antiporter, sodium/hydrogen antiporter-1 (NHE1) (Be-
hne et al, 2002, 2003; Fluhr et al, 2004a), have all been
shown to play a role in SC acidification.
Both a fully developed cornified envelope (Hardman et al,
1998; Komuves et al, 1998; Lee et al, 1999) and abundant
extracellular lamellar membranes (Hanley et al, 1997; Will-
iams et al, 1998; Hanley et al, 1999) are generated in the SC
late in gestation. Hence prior to birth, the fetus develops a
cutaneous permeability barrier sufficient for survival in a
terrestrial environment. But skin surface pH is neutral at
birth both in humans and in rodents (Behrendt and Green,
1958; Visscher et al, 2000; Yosipovitch et al, 2000; Fluhr
et al, 2004a). In humans it takes several weeks to months
before the SC is fully acidified whereas in the neonatal rat
the SC attains normal adult pH levels over the first postnatal
week (Behrendt and Green, 1958; Visscher et al, 2000;
Yosipovitch et al, 2000; Fluhr et al, 2004a). Recent studies
by our laboratory have shown in rodents that sPLA2 activity
Abbreviations: 22(R)-Chol, 22(R)-hydroxycholesterol; aSM’ase, ac-
id sphingmyelinase; BPB, bromphenacylbromide; DMSO, dimethyl
sulfoxide; DSG1, desmoglein 1; b-Gluc Cer’ase, b-glucocerebro-
sidase; LXR, Liver X receptor activators; NHE-1, sodium/hydrogen
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sPLA2, secretory phospholipase A2; TEWL, transepidermal water
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is low at birth but increases progressively after birth (Fluhr
et al, 2004a). Moreover, inhibition of sPLA2 activity delays
postnatal SC acidification. The NHE1 antiporter is ex-
pressed at birth and inhibition of this transporter also delays
SC acidification in the neonatal period (Behne et al, 2003;
Fluhr et al, 2004a). Conversely, neither microbial coloniza-
tion nor urocanic acid appears to play a key role in neonatal
acidification (Fluhr et al, 2004a). Thus, the postnatal acid-
ification of the SC can be attributed, at least in part, to
sPLA2 and NHE1 (Behne et al, 2003; Fluhr et al, 2004a) and
sPLA2 and NHE1 have been identified to be key sources of
endogenous SC acidification.
Traditionally the major function of the acid SC-buffer
system has been assumed to be antimicrobial (Aly et al,
1975; Hartmann, 1983; Bibel et al, 1989). But recent studies
have demonstrated abnormalities in the function of the SC
in the neonatal period, which are because of the lack of an
acidic SC at birth (Fluhr et al, 2004a). Specifically, although
basal permeability barrier function is competent in neon-
ates, the recovery of permeability barrier function following
acute barrier disruption is delayed (Fluhr et al, 2004b). The
delay in barrier recovery was attributed to incompletely
processed lamellar membranes in the SC because of a de-
crease in the activity of a key enzyme for lipid processing
during SC maturation; b-glucocerebrosidase, an enzyme
whose optimal activity is at an acidic pH. Both the abnor-
mality in permeability barrier homeostasis and the structural
abnormality of the lamellar membranes could be corrected
by topical treatment with an acidic buffer, which normalized
b-glucocerebrosidase activity (Fluhr et al, 2004b). In addi-
tion to the abnormality in permeability homeostasis, a de-
crease in SC integrity also was seen in newborn rats. The
decrease in SC integrity was attributed to a decrease in the
density of corneodesmosomes (CD), with an associated
decrease in desmoglein 1 and corneodesmosin protein ex-
pression in the neonatal SC (Fluhr et al, 2004b). CD are key
structures for SC cohesion and desmoglein 1 is one of the
major proteins of CD. Alteration in CD density correlate with
changes in SC integrity and cohesion. Topical treatment
with an acidic buffer again increased the number of CD and
restored SC integrity to normal (Fluhr et al, 2004b). Thus,
the delay in acidification of neonatal skin results in func-
tional abnormalities that could have adverse clinical con-
sequences for the newborn.
Liver X receptor (LXR) are members of the nuclear hor-
mone receptor superfamily, which form heterodimers with
RXR, in order to activate gene transcription. Two genes, a
and b, encode the LXR paralogues. LXRa is expressed
predominately in the liver and to a lesser extent in the kid-
ney, spleen, adrenal gland, and the small intestine (Willy
et al, 1995), whereas LXRb is ubiquitously expressed (Song
et al, 1995). Our laboratory has shown that both LXRa and
LXRb are present in cultured human keratinocytes and in
fetal rat epidermis (Hanley et al, 1999, 2000). LXRa and
LXRb are now recognized to bind oxysterols, including
22(R)-hydroxycholesterol (22(R)-Chol), 24(S)-hydroxycho-
lesterol, and 24(S),25-epoxycholesterol. Activation of LXR
regulates important pathways in cholesterol, fatty acid, and
bile acid metabolism. Recently, we demonstrated that top-
ical application of oxysterols to murine epidermis and the
addition of oxysterols to human keratinocyte cultures stim-
ulate keratinocyte differentiation (Fowler et al, 2003;
Schmuth et al, 2004, 2005). In addition, topical oxysterol
treatment of normal adult animals improves permeability
barrier homeostasis following acute barrier disruption
(Komuves et al, 2002). Furthermore, in an animal model of
epidermal hyperplasia, oxysterol treatment restored epider-
mal morphology towards normal by both inhibiting prolifer-
ation and stimulating differentiation (Komuves et al, 2002).
Finally, and of particular pertinence to this manuscript, oxy-
sterols also accelerate the formation of the epidermal per-
meability barrier and stimulate differentiation during fetal
development (Hanley et al, 1999, 2000). Thus, activation of
LXR improves epidermal function in a variety of experimental
models. We therefore hypothesized that treatment of neo-
natal rat skin with LXR activators could stimulate acidification
and normalize the previously described abnormalities in
cutaneous function that occur in the neonatal epidermis.
Results
Topical LXR activators accelerate postnatal acidiﬁca-
tion in neonatal rats In separate experiments, topical
treatment of newborn mice for 3 d with three chemically
unrelated LXR activators, an oxysterol, 22(R)-Chol, and two
non-oxysterol pharmacologic activators of LXR, TO-901317
and GW 3965, stimulated the acidification of neonatal skin
(Fig 1). In contrast, topical treatment with cholesterol, a
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Figure1
Topical treatment with liver X receptor (LXR) ligands accelerates
acidification of the stratum corneum (SC). (A) Newborn animals were
treated topically with GW 3965, an LXR ligand, twice a day for 3 d. On
day 3, SC surface pH was measured (N¼ 7; mean  SEM). (B) New-
born animals were treated topically with cholesterol, 22(R)-hydroxy-
cholesterol or TO-901317 twice a day for 3 d. On day 3, SC surface pH
was measured. For both sets of experiments the compounds were
dissolved in acetone at a concentration of 10 mM. The newborn rats
were treated on each flank twice per day over 3 d with 20 mL of the
freshly prepared solutions. In order to prevent the mothers from licking
the applied substances off the newborn rats, we placed the pups in a
plastic container in a 371C incubator for 2–3 h. The measurements were
performed after 3 d of treatment (N¼7; mean  SEM).
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sterol compound that does not activate LXR, did not stim-
ulate acidification. Similar to studies in adult rodents, topical
treatment with LXR activators stimulated the expression of
loricrin, involucrin, and filaggrin in the newborn rats treated
with 22(R)-Chol (data not shown).
LXR activators normalize SC structure and function in
neonatal rats We next determined whether topical treat-
ment with LXR activators would improve the abnormality in
permeability barrier homeostasis that occurs in newborn
rodents. As shown in Fig 2, topical treatment with 22(R)-
Chol accelerated barrier recovery following acute disruption
of the barrier by tape stripping. The control group in Fig 2
shows a slight delay in barrier recovery compared with un-
treated neonatal rat (Fluhr et al, 2004b). The control group
was treated with the solvent (acetone) for 3 d, which may
partially explain the delay in barrier recovery. The improve-
ment in barrier homeostasis was associated with a normal-
ization of lamellar membrane maturation in the SC on
qualitative analysis of the electron micrographs (Fig 3B
vs A). Vehicle-treated neonates demonstrated extracellular
lamellar membranes that were immature i.e. incompletely
processed (Fig 3A), whereas in oxysterol-treated animals
the lamellar membranes were more mature in appearance
(i.e., completely processed) (Fig 3B). LXR-treated neonatal
membrane structures were identical, i.e., as mature, as
membranes seen in day 5 neonatal rat epidermis (Fig 4A).
A key enzyme required for the processing of secreted
lamellar body lipid precursors to their more hydrophobic
counterparts that form mature lamellar membranes is b-
glucocerebrosidase. As shown in Fig 5 (available online in
color as Fig S1), treatment with 22(R)-Chol increases the
in situ activity of b-glucocerebrosidase. These results show
first that activation of LXR improves permeability barrier
homeostasis in neonatal rats, and second, that the basis
for such improvement is acceleration of lipid processing
Figure 2
Permeability barrier homeostasis is improved by topical treatment
with liver X receptor (LXR) ligands. Newborn animals were treated
topically twice per day for 3 d with 22(R)-hydroxycholesterol (22(R)-
Chol)). To quantify epidermal permeability barrier function and barrier
homeostasis, we measured transepidermal water loss (TEWL) with an
electrolytic water analyzer (MEECO). After acute barrier disruption by
tape stripping with a TEWL value of approximately 10–15  over
baseline, barrier recovery rates were calculated with the following for-
mula: 1(TEWL immediately after strippingTEWL at different time
points)/(TEWL immediately after strippingbaseline TEWL)  100%
(N¼9 for 22(R)-Chol and N¼6 for the control group; mean  SEM).
Figure3
Liver X receptor (LXR) activators accelerate mat-
uration of extracellular lamellar membranes in
neonatal rat stratum corneum (SC). Neonates
were treated twice daily with either 22(R)-hydroxy-
cholesterol or vehicle for 3 d as described in ‘Meth-
ods.’ Three hours after barrier disruption by tape
stripping samples were obtained and prepared for
EM analysis as described in ‘Methods’. Although
incompletely processed ‘‘immature’’ membranes
predominate in vehicle-treated animals (A, arrows),
in the LXR-treated animals membrane structure was
normalized (B, arrows). (A, B) Ruthenium tetroxide
post-fixation. (Scale bar¼ 0.25 mm).
Figure4
Liver X receptor (LXR) activators normalize corneodesmosome
density and size. (A, B) Differences in membrane maturation (arrows)
of untreated newborns (B) versus 5 d-old animals (A). (C, D) Neonates
were treated twice daily with either 22(R)-hydroxycholesterol or vehicle
for 3 d as described in ‘Methods.’ LXR activators both increase CD
density and the size of individual CD (arrowheads D vs C). (A, B) Ru-
thenium tetroxide post-fixation. (C, D) Osmium tetroxide fixation. Scale
bar¼0.25 mm.
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leading to the formation of mature lamellar membranes, a
sequence that requires activation of b-glucocerebrosidase.
In addition to normalizing permeability barrier home-
ostasis, topical treatment with 22(R)-Chol also improved SC
integrity and cohesion in neonatal rats (Fig 6). This im-
provement in SC integrity was associated with a qualitative
increase in both the density and size of CD in the lower SC
(Fig 4D vs C). These LXR-induced changes in CD correlated
with an increase in the expression of desmoglein 1 (Fig 7,
available online in color as Fig S2). The pictures are rep-
resentative of the results of several independent experi-
ments.
In this and other studies (Fluhr et al, 2001a, 2004b;
Hachem et al, 2003) we have noted that CD size is altered
whereas in normal SC the size of the CD is fairly constant. It
is likely that in altered states, such as when the SC pH is
increased, there is increased catabolism of CD, which
results in greater variations in CD size than normally
observed.
Basis for the accelerated acidiﬁcation by LXR activa-
tors To gain insights into the mechanism by which LXR
activators accelerate SC acidification, we next measured
sPLA2 activity in the epidermis and SC after treatment with
22(R)-Chol. As shown in Fig 8, sPLA2 activity increased fol-
lowing treatment with 22(R)-Chol. Moreover, blockade of
sPLA2 activity with bromophenacyl bromide (BPB), a sui-
cide inhibitor of sPLA2, prevents the acceleration of SC
acidification induced by treatment with LXR activators (Fig
9). In contrast, immunofluorescent staining did not reveal a
difference in NHE1 levels in LXR-versus vehicle-treated an-
imals (data not shown). Together, these results suggest that
stimulation of sPLA2 activity is one mechanism that ac-
counts for LXR acceleration of SC acidification.
Discussion
It is well recognized that the skin surface pH is neutral at
birth in humans and in various animal models (Behrendt and
Figure 5
The activity of b-glucocerebrosidase in neonatal rat stratum corn-
eum (SC) is increased by treatment with Liver X receptor (LXR)
ligands. Newborn animals were treated topically twice per day for 3 d
with 22(R)-hydroxycholesterol. Twelve hours after the last treatment
skin was obtained. Enzyme activity was measured by applying 20 mL of
10 mM resorufin b-D-glucopyranoside dissolved in dimethyl sulfoxide to
the backs of the newborn rats. The resorufin dye becomes fluorescent
once the substrate is enzymatically cleaved. Following topical appli-
cation, neonatal pups were placed for 2–3 h in a plastic container at
371C–381C, as above. At the end of these in vivo incubations, 4-mm
punchout biopsies were taken from treated and control sites. The bi-
opsies were placed on a plastic coverslip with a punched out center,
inverted onto a microscopic slide, and covered with a second, non-
punched coverslip. The cleaved compound was visualized with a con-
focal microscope at an excitation wavelength of 568 nm and an
emission wavelength of 580 nm. Resorufin alone served as an addi-
tional negative control and as a further check for specificity (data not
shown). b-Glucocerebrosidase enzyme activity was blocked when the
fluorogenic substrate was coapplied with 10 mM conduritol B epoxide
(data not shown). Low levels of enzyme activity in the inter-cellular
spaces of the SC were observed in vehicle-treated control animals (B,
D), whereas treatment with two LXR ligands, 22(R)-hydroxycholesterol
( A) and GW 3965 (C), both markedly increased enzyme activity (Scale
bar-20 mm).
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Figure6
Both stratum corneum (SC) integrity and cohesion are improved by
treatment with Liver X receptor (LXR) ligands. Newborn animals
were treated topically twice per day for 3 d with 22(R)-hydroxycholes-
terol. Twelve hours after the last treatment SC integrity was assessed
as the change in transepidermal water loss (TEWL) value after a pre-
defined number of D-Squame tape strippings (3  ) (A). The increase in
TEWL was markedly reduced by treatment with the LXR ligand 22(R)-
hydroxycholesterol (po0.0001; n¼ 9 vs 10). SC cohesion was as-
sessed as the amount of protein removed per D-Squame stripping as
described in detail in ‘Methods.’ The amount of protein removed by
tape stripping was decreased following treatment with the LXR ligand
22(R)-hydroxycholesterol (B) (po0.0001; n¼ 16 vs 18).
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Green, 1958; Aszterbaum et al, 1992; Hoath et al, 1992,
1993; Visscher et al, 2000; Yosipovitch et al, 2000; Fluhr
et al, 2004a). Human SC does not achieve adult levels of
acidification for several weeks whereas in rodent models
the time for acidification is compressed such that adult pH
levels are achieved in several days. This delay in SC acid-
ification results in abnormalities in permeability barrier
homeostasis and a decrease in SC integrity and cohesion
(Fluhr et al, 2004b). The combination of a decrease in the
ability of the SC to withstand mechanical injury (SC integrity
and cohesion) and a delay in the ability of the epidermis to
repair injuries (permeability barrier homeostasis) would re-
sult in an increased susceptibility to cutaneous dysfunction
with an adverse impact on the neonate. It is well recognized
by clinical neonatologists and pediatric dermatologists that
newborn skin, even in unoccluded non-diapered areas, is
more susceptible to injury (Behrendt and Green, 1958;
Brook, 1992; Yosipovitch et al, 2000). Finally, occluded in-
fant skin is much more susceptible to injury and inflamma-
tion and we would speculate that these propensities may
be partially explained by the pH-linked abnormalities in
permeability barrier homeostasis and SC integrity and
cohesion.
In addition to the abnormalities in permeability barrier
homeostasis and SC integrity and cohesion that occur with
an elevated pH, it is well recognized that skin pathogens,
such as Staphylococcus aureus and Streptococcus pyo-
genes, grow better at a neutral pH than an acidic pH. In
Figure 7
Desmoglein 1 (DSG) Expression is increased by topical treatment with Liver X receptor (LXR)-ligands. Newborn animals were treated topically
twice per day for 3 d with 22(R)-hydroxycholesterol, TO-901317, or vehicle. Twelve hours after the last treatment skin was obtained. DSG 1
expression was measured on paraffin tissue sections from newborn rat skin. The sections were incubated for 30 min in blocking buffer and then
incubated for 2 h at room temperature with 1:500 dilution of a primary, polyclonal, rabbit anti-mouse DSG 1 antibody. The tissue then was washed
with PBS and incubated for 1 h at room temperature with goat anti-rabbit IgG Alexa-labeled secondary antibodies and visualized directly in a
confocal microscope (Leica TCS SP, Heidelberg, Germany) at an excitation wavelength of 488 nm and an emission wavelength of 518 nm. (A) 22(R)-
hydroxycholesterol, (B) vehicle control, (C)- TO-901317 (Scale bar¼ 10 mm).
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Figure 8
Secretory phospholipase A2 (sPLA2) activity is increased by topical
treatment with Liver X receptor (LXR) ligands. Newborn animals
were treated topically twice per day for 3 d with 22(R)-hydroxycholes-
terol or vehicle (control). Twelve hours after the last treatment skin was
obtained. sPLA2 activity was assessed in pooled, sequential SC tape
strips with a fluorometric assay after 3 d of treatment. To ensure uni-
form removal, the D-Squame tapes were placed on the skin surface
with forceps, and the tape surface was gently rubbed three times over
its entire surface. The tapes were stored individually in glass scintil-
lation vials at 41C until assayed. Total sPLA2 activity in stratum corneum
(SC) was quantified as the release of pyrenyldecanoic acid from 1-
hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phophocholine. Flu-
orescence was monitored with a spectrofluorometer at excitation and
emission wavelengths of 341 and 376 nm, respectively. The activity of
sPLA2 was calculated per cm
2 of total SC (N¼ 6; mean  SEM).
Figure9
Co-applications of bromphenacyl bromide (BPB) inhibited the
stratum corneum (SC) acidification induced by treatment with liver
X receptor (LXR) ligands. Newborn animals were treated topically with
BPB alone, 22(R)-hydroxycholesterol alone or both BPB and 22(R)-
hydroxycholesterol twice a day for 3 d. On day 3, SC surface pH was
measured (N¼9; mean  SEM).
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contrast, normal skin flora grows poorly above pH 6.5 but
flourishes at an acidic pH (Puhvel et al, 1975; Korting et al,
1990, 1992). Thus, the acidic pH of the SC discourages
colonization and growth of pathogenic microorganisms and
supports the growth of normal nonpathogenic microbial
flora. Accordingly, the increased susceptibility to cutaneous
infection in neonates may in part be related to their high
SC pH.
Given the delay in SC acidification and the potential
harmful consequences of an elevated SC pH in newborns
we have begun to assess the impact of different approach-
es that could accelerate the acidification of the SC in the
neonatal period. Topical application of either acidic buffers
or superacids acidifies the SC and improves the defect in
permeability barrier homeostasis and SC integrity and co-
hesion (Hachem et al, 2003). Previous studies by our group
have shown that LXR activators accelerate the develop-
ment of the epidermis during fetal development (Hanley
et al, 1999) and in adult animals stimulate epidermal differ-
entiation (Komuves et al, 2002) and improve permeability
barrier homeostasis. In this manuscript we demonstrate
that topical treatment of newborn rat skin with three differ-
ent LXR activators (an oxysterol and two nonsterol activa-
tors) accelerates the acidification of newborn SC. In
contrast, cholesterol, a sterol that does not activate LXR,
had no effect on SC acidification.
Even more importantly, topical treatment with LXR acti-
vators improved the functional defects in newborn animals.
Specifically, both permeability barrier homeostasis and SC
integrity and cohesion were improved in the LXR-activator-
treated animals. The improvement in permeability barrier
function was associated with an increase in b-glucocer-
ebrosidase activity in the SC, a key enzyme for lipid
processing during lamellar bilayer maturation. Subsequent-
ly the appearance of more mature lamellar membranes in
the extracellular spaces of the SC could be observed. It is
well known that the activity of b-glucocerebrosidase activity
is optimal at pH 5.5 and that this enzyme plays a key role in
the formation of the mature lamellar membranes in SC that
are essential for barrier function (Holleran et al, 1992–1994;
Takagi et al, 1999). Hence one can speculate that the
decrease in SC pH induced by LXR activator treatment
improved barrier function by increasing the activity of
b-glucocerebrosidase.
The improvement in SC integrity and cohesion was as-
sociated with an increase in the size and density of CD, a
key structure in regulating SC integrity and cohesion. In
addition, staining of desmoglein 1, one of the major proteins
of CD, was increased in the SC of LXR-activator-treated
animals. One can speculate that by dereasing SC pH that
the activity of SC proteases would be decreased therebv
slowing the catabolism of CD. In prior studies we have
shown that increasing SC pH increases serine protease
activity in the SC, which is associated with a decrease in
both the size and density of CD (Hachem et al, 2003). Thus,
the structural abnormalities that account for the decrease in
permeability barrier homeostasis and SC integrity and co-
hesion are corrected by topical treatment of newborn rat
skin with LXR activators. One would anticipate that this
improvement in permeability barrier homeostasis and SC
integrity and cohesion would decrease the skin’s suscep-
tibility to injury and improve the repair process thereby po-
tentially decreasing cutaneous disorders in the neonatal
period.
Although increases in SC pH could account for the cor-
rection of both the abnormalities in permeability home-
ostasis and SC integrity and cohesion in neonatal skin it
should be recognized that LXR activators could have other
effects that could contribute to the correction of these ab-
normalities. Specifically, in studies of adult skin we have
demonstrated that LXR activators improve barrier function
independent of changes in pH (Komuves et al, 2002). In
addition in both neonates and adults LXR activators stim-
ulate keratinocyte differentiation. Thus, it is likely that al-
though the decrease in pH plays a role in the improved
function of neonatal skin following LXR activator treatment
other factors probably also contribute.
The mechanisms by which SC acidification occurs are
very complex and diverse and include both exogenous and
endogenous mediators. Previous studies by our laboratory
have suggested a role for sPLA2 and NHE1 in the acidifi-
cation of the SC during the neonatal period (Behne et al,
2003; Fluhr et al, 2004a). In this study we demonstrate that
sPLA2 activity is increased by topical treatment with LXR
activators whereas NHE1 levels were not altered. Addition-
ally, inhibiting sPLA2 activity with BPB prevented the acid-
ification of the SC induced by LXR activators. Together
these results suggest that LXR activation of SC sPLA2 ac-
tivity may contribute to the acceleration of SC acidification
but it must be recognized that many pathways contribute to
SC acidification and it is likely that LXR activators may work
by affecting multiple pathways.
In summary these studies demonstrate that LXR activa-
tors can accelerate acidification of the SC during the neo-
natal period and correct the abnormalities in permeability
barrier homeostasis and SC integrity and cohesion that oc-
curs in newborn animals. These studies suggest the pos-
sibility that LXR activators could be of clinical benefit in the
prevention and/or treatment of cutaneous disorders during
the neonatal period.
Methods
Materials and animal procedures Timed-pregnant Sprague–
Dawley rats were obtained from Simonson Laboratories (Gilroy,
California) and fed Purina mouse diet and water ad libitum. The
LXR ligands were obtained as follows: GW 3965 was a gift from Dr
Willson, Glaxo-Smith-Kline, TO-901317 was purchased from
BIOMOL International (Plymouth Meeting, Pennsylvania) and
22(R)-Chol was purchased from Sigma-Aldrich (St Louis, Missou-
ri). The compounds were dissolved in acetone at a concentration of
10 mM. The newborn rats were treated on each flank 2  per day
over 3 d with 20 mL of the freshly prepared solutions. In order to
prevent the mothers from licking the applied substances off the
newborn rats, we placed the pups in a plastic container in a 371C
incubator for 2–3 h. The pups were placed in groups (vehicle
treated separated from activator treated). It has been reported that
even short-term maternal deprivation results in decreases in liver
enzyme activities, e.g. ornithine decarboxylase (Schanberg et al,
2003). But the fact that both the control and LXR-activator-treated
groups were separated from their mother ensures that both groups
were comparable. The measurements were performed after 3 d of
treatment.
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Barrier function was determined by measurement of transep-
idermal water loss (TEWL) with an electrolytic water analyzer
(MEECO, Warrington, Pennsylvania). Surface pH was measured
with a flat, glass surface electrode from Mettler-Toledo (Giessen,
Germany), attached to a pH meter (Skin pH Meter PH 900, Cour-
age & Khazaka, Cologne, Germany). Propylene glycol and ethanol
were from Fisher Scientific (Fairlane, New Jersey), whereas BPB
was from Sigma Chemical Co. (St Louis, Missouri). EnzCheck
Protease Assay Kit was purchased from Molecular Probes
(Eugene, Oregon). The strippings were performed with 22 mm
D-Squame 100 tapes, purchased from CuDerm (Dallas, Texas). To
assess the importance of sPLA2, neonatal animals were treated
topically twice daily for 3 d with BPB (4 mg per mL) in propylene
glycol: ethanol (7:3, vol/vol) vehicle or the vehicle alone applied to
the backs and flanks of the newborn rats ( 10 mL per cm2) as
described previously for hairless mice (Mao-Qiang et al, 1996;
Fluhr et al, 2001a). The inhibitor doses that we employed have
been shown previously to inhibit sPLA2 activity selectively in dif-
ferent tissues and cell types (Jain et al, 1991; Gelb et al, 1994) and
to be nontoxic to murine skin, without evidence of inhibition of
other synthetic activities (Mao-Qiang et al, 1995, 1996). The animal
procedures were approved by the Animal Studies Committee of
the San Francisco Veterans Affairs Medical Center and were per-
formed in accordance with the guidelines.
SC integrity and barrier homeostasis SC integrity was assessed
as the change in TEWL value after a predefined number of D-
Squame tape strippings. After acute barrier disruption by tape
stripping with a TEWL value of about 10–15  over baseline, bar-
rier recovery rates were calculated with the following formula:
1(TEWL immediately after strippingTEWL at different time
points)/(TEWL immediately after strippingbaseline TEWL) 
100%.
Electron microscopy Samples for electron microscopy were
minced to 1 mm3 cubes, placed in modified Karnovsky’s fixative,
and post-fixed in either reduced 1% osmium or buffered 0.2%
ruthenium tetroxide with 0.5% ferrocyanide (Hou et al, 1991).
Samples were examined in a Zeiss 10A electron microscope (Carl
Zeiss, Thornwood, New York) operated at 60 kV. Pictures shown
for both light and electron microscopy are representative of the
changes observed in three or more samples obtained from at least
two different litters, for each treatment.
sPLA2 activity sPLA2 activity was assessed in pooled, sequential
SC tape strips (D-Squame) with a fluorometric assay, as described
by (Radvanyi et al, 1989; Mazereeuw-Hautier et al, 2000). Briefly,
sequential tape strips were collected down to the glistening layer,
that is, until the surface of the newborn rats was shiny. In newborn
rats the SC was stripped down to the glistening layer after 3 d of
treatment twice per day. To ensure uniform removal, the D-Squame
tapes were placed on the skin surface with forceps, and the tape
surface was gently rubbed three times over its entire surface. The
tapes were stored individually in glass scintillation vials at 41C until
assayed as described (Fluhr et al, 2004a).
In situ zymographic assay of b-glucocerebrosidase activity
Enzyme activity was measured using a modification of a previously
described method (Takagi et al, 1999) that has been previously em-
ployed in neonatal rat studies (Hachem et al, 2003; Fluhr et al,
2004b).
Desmoglein 1 (DSG 1) expression DSG 1 expression was vis-
ualized as described previously (Fluhr et al, 2001a).
NHE1 expression Rabbit anti-mouse NHE1 antibody was pur-
chased from Chemicom (Temecula, California) and FITC-labeled
goat anti-rabbit antibody was purchased from Jackson Immuno-
research Laboratories Inc. (West Grove, Pennsylvania). Skin biop-
sies were taken after 3 d of vehicle or LXR activator treatment. ten
micrometer sections were incubated with NHE1 antibody at a
concentration of 15 mg per mL for 2 h at room temperature. 1:200
dilution of FITC-labeled secondary was applied to sections and
incubated for 30 min at room temperature.
Statistical analyses Statistical analyses were performed using
Prism 3 (GraphPad Software Inc., San Diego, California). Normal
distribution was tested before calculating the comparison with an
unpaired t-test. In experiments with more than three groups, an
ANOVA was calculated followed by an a-corrected post hoc test
(Bonferroni). Values are expressed as mean  SEM. The signifi-
cance level was set at po0.05.
This study was supported by NIH grants AR 39448 (PP), AR050629,
HD29706, and the Medical Research Service, Department of Veterans
Affairs.
Supplementary Material
The following material is available online for this article.
Figure S1
The activity of beta-glucocerebrosidase in neonatal rat stratum
corneum is increased by treatment with LXR-ligands. Newborn an-
imals were treated topically twice per day for 3 days with 22(R)-hydro-
xycholesterol. Twelve hours after the last treatment skin was obtained.
Enzyme activity was measured by applying 20 mL of 10 mM resorufin
b-D-glucopyranoside dissolved in dimethyl sulfoxide to the backs of
the newborn rats. The resorufin dye becomes fluorescent once the
substrate is enzymatically cleaved. Following topical application, neo-
natal pups were placed for 2 to 3 h in a plastic container at 371C to
381C, as above. At the end of these in vivo incubations, 4-mm punchout
biopsies were taken from treated and control sites. The biopsies were
placed on a plastic coverslip with a punched out center, inverted onto a
microscopic slide, and covered with a second, nonpunched coverslip.
The cleaved compound was visualized with a confocal microscope at
an excitation wavelength of 568 nm and an emission wavelength of 580
nm. Resorufin alone served as an additional negative control and as a
further check for specificity (data not shown). Beta-Glucocerebrosidase
enzyme activity was blocked when the fluorogenic substrate was co-
applied with 10 mM conduritol B epoxide (data not shown).
Figure S2
Desmoglein 1 Expression is increased by topical treatment with
LXR-ligands. Newborn animals were treated topically twice per day for
3 days with 22(R)-hydroxycholesterol, TO-901317, or vehicle. Twelve
hours after the last treatment skin was obtained. Desmoglein 1 ex-
pression was measured on paraffin tissue sections from newborn rat
skin. The sections were incubated for 30 min in blocking buffer and
then incubated for 2 h at room temperature with 1:500 dilution of a
primary, polyclonal, rabbit anti-mouse DSG 1 antibody. The tissue then
was washed with PBS and incubated for 1 h at room temperature with
goat anti-rabbit IgG Alexa-labeled secondary antibodies and visualized
directly in a confocal microscope (Leica TCS SP, Heidelberg, Germany)
at an excitation wavelength of 488 nm and an emission wavelength of
518 nm. Panel A- 22(R)-hydroxycholesterol, Panel- B vehicle control,
Panel C- TO-901317 Magnification bars ¼ 10 mm.
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